German Biotech: Coalescing around the Haves
Executive Summary
Positive signs are coming out of German biotech for the first time in years. Scientific output remains strong. The subsector boasts its first profitable pharmaceutical-oriented company; several on- or near-market products, and even a nascent IPO market. The fact that dozens of companies are expected to go bust this year is another sign of the industry's maturation. The long-awaited consolidation predicted in the wake of the Neuer Markt demise is seemingly finally happening. The have-nots are finally beginning to cluster around the haves.
You may also be interested in...
Pushing Ahead with IPOs in Europe
European private companies and VCs are faring no better than their US counterparts when it comes to IPOs so far in 2005. But a series of bad haircuts and poor aftermarket performances hasn't scared everybody off, yet.
Pushing Ahead with IPOs in Europe
European private companies and VCs are faring no better than their US counterparts when it comes to IPOs so far in 2005. But a series of bad haircuts and poor aftermarket performances hasn't scared everybody off, yet.
Challenging Times for European Biotech IPOs
Through the first week of May, 2005, five biotechs listed on Europe's main markets. Like their counterparts in the US, these companies have had to deal with difficult public markets and have on the whole raised much less money than they originally intended.